Indiana University-Purdue University Indianapolis (IUPUI) / Methylmercury (MeHg) exposure from occupational, environmental and food sources is a significant threat to public health. MeHg poisonings in adults may result in severe psychological and neurological deficits, and in utero exposures can confer significant damage to the developing brain and impair neurobehavioral and intellectual development. Recent epidemiological and vertebrate studies suggest that MeHg exposure may contribute to dopamine (DA) neuron vulnerability and the propensity to develop Parkinson’s disease (PD). I have developed a novel Caenorhabditis elegans (C. elegans) model of MeHg toxicity and have shown that low, chronic exposure confers embryonic defects, developmental delays, reduction in brood size, decreased animal viability and DA neuron degeneration. Toxicant exposure results in an increase in reactive oxygen species (ROS) and the robust induction of several glutathione-S-transferases (GSTs) that are largely dependent on the PD-associated phase II antioxidant transcription factor SKN-1/Nrf2. I have also shown that SKN-1 is expressed in the DA neurons, and a reduction in SKN-1 gene expression increases MeHg-induced animal vulnerability and DA neuron degeneration. Furthermore, I incorporated a novel genome wide reverse genetic screen that identified 92 genes involved in inhibiting MeHg-induced animal death. The putative multidrug resistance protein MRP-7 was identified in the screen. I have shown that this transporter is likely expressed in DA neurons, and reduced gene expression increases cellular Hg accumulation and MeHg-associated DA neurodegeneration. My studies indicate that C. elegans is a useful genetic model to explore the molecular basis of MeHg-associated DA neurodegeneration, and may identify novel therapeutic targets to address this highly relevant health issue.

Indiana University-Purdue University Indianapolis (IUPUI) / Choroidal neovascularization (CNV) is the vision-threatening characteristic of wet age-related macular degeneration (AMD), a major cause of blindness affecting almost 2 million elderly Americans. The current approved treatments target the dominant angiogenic mediator, vascular endothelial growth factor (VEGF). However, repeated injections of anti-VEGF drugs can cause ocular and systemic side effects, and about 30% of wet AMD patients are non-responsive. There is thus an unmet need to develop VEGF-independent antiangiogenic molecules to complement or combine with existing medications. I studied SH-11037, a novel homoisoflavonoid with potent and selective antiangiogenic activity against human retinal endothelial cells. Intravitreal SH- 11037 dose-dependently suppressed angiogenesis in the laser-induced CNV (LCNV) mouse model. These effects were prominent as early as 7 days post-laser treatment as measured by a novel ellipsoid quantification method of optical coherence tomography images in vivo. A supratherapeutic dose of 100 μM SH- 11037 was not associated with signs of murine ocular toxicity, and did not interfere with pre-existing retinal vasculature or retinal function. SH-11037 synergized with anti-VEGF therapy in vitro and in vivo, suggesting a VEGFindependent mechanism. By photoaffinity pulldown, I identified soluble epoxide hydrolase (sEH) as an SH-11037-binding target. sEH is a key enzyme in ω-3 and ω-6 fatty acid metabolism. sEH levels were dramatically upregulated in retinal sections from L-CNV mice and a specific sEH inhibitor, t-AUCB, significantly suppressed L-CNV lesion volume. Additionally, SH-11037 inhibited sEH enzymatic activity in vitro and in vivo in L-CNV mice. Given the role of sEH in the metabolism of docosahexaenoic acids (DHA), inhibition of sEH using small molecules like SH-11037 would enhance ocular DHA levels, with beneficial antiangiogenic and anti-inflammatory effects. SH-11037 is thus a novel sEH inhibitor, which could make it an alternative or additive therapy to existing anti- VEGF drugs for treatment of neovascular diseases in the eye and other tissues.

Indiana University-Purdue University Indianapolis (IUPUI) / Prevention of pathological angiogenesis is a key strategy for treatment of common blinding ocular diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degeneration. The current treatment strategies are associated with partial vision loss and are ineffective in a significant patient population. Hence novel drugs as well as new ways to target ocular angiogenesis are needed for treating these diseases. I pursued a natural antiangiogenic compound, cremastranone, to develop novel drug leads and to find new targets. The objective of my doctoral thesis project was to elucidate cremastranone’s molecular mechanism of action and optimize its structureactivity relationship (SAR). In order to achieve this goal, with the help of chemistry collaborators cremastranone was synthesized for the first time. I showed that cremastranone has 50-fold more potency against endothelial cells as compared to nonendothelial cells, and also tested a novel active isomer, SH-11052. By SAR studies I identified a potent molecule, SH-11037, that has 10-fold more selectivity against retinal endothelial cells as compared to macrovascular endothelial cells. I then elucidated cremastranone’s molecular mechanism using a chemical proteomic approach. I identified ferrochelatase (FECH) as a specific interacting protein partner of cremastranone using photoaffinity chromatography. Hence, I hypothesized that cremastranone exerts its antiangiogenic activities through modulation of the functions of FECH. Cremastranone inhibited the enzymatic activity FECH in endothelial cells. Therefore, I investigated the role of FECH in ocular angiogenesis. Partial loss of FECH, using a siRNA-based knock down approach, decreased retinal angiogenesis both in vitro and in vivo in mouse models. Knock down of FECH decreased the expression levels of key proangiogenic proteins HIF-1α, eNOS, and VEGFR2. This work suggests that ferrochelatase plays an important, previously undocumented role in angiogenesis and that targeting of this enzyme by cremastranone might be exploited to inhibit pathological angiogenesis in ocular diseases.

Indiana University-Purdue University Indianapolis (IUPUI) / The etiology of many neurodegenerative diseases is unknown, but a number of studies indicate that a combination of both genetic and environmental factors contribute to the progression of disease. Exposure to environmental metals, such as Mn2+, Fe2+, Cu2+, and Al3+, has been shown to increase cell death that is characteristic of neurodegenerative disorders such as AD, PD, Wilson’s disease and Menkes disease. These metals are important in numerous biological processes in the brain and their homeostasis is regulated through multiple mechanisms of transport, storage, and secretion. The vertebrate divalent metal transporter-1 (DMT-1) has been implicated in transport and homeostasis of these divalent cations. In these studies I utilize Caenorhabditis elegans (C. elegans) to show that long term exposure to Mn2+ decreases animal viability in a dose-dependent manner, and I demonstrate that C. elegans homologues to DMT-1, SMF-1, SMF-2, and SMF-3, play specific roles in divalent metal ion-induced DA neurodegeneration. I show that SMF-1 contributes to Fe2+-induced DA neuron degeneration, SMF-3 contributes to Al3+-induced DA neuron degeneration, and both SMF-2 and DAT-1 contribute to Cu2+-induced DA neuron cell death. These studies utilize C. elegans as a powerful model to characterize molecules and pathways involved in metal toxicity and metal-induced DA neuron degeneration.

Los fotorreceptores de los mamíferos, las células externas de la retina que detectan la luz, carecen de capacidad de autorregeneración tras una lesión. En los estadios avanzados de las IRD, los fotorreceptores se pierden pero la estructura interna de la retina se conserva durante largos periodos de tiempo, aunque con una importante remodelación sináptica y gliosis. Para estas condiciones, las terapias regenerativas dirigidas a reemplazar los fotorreceptores y establecer sinapsis funcionales con las neuronas internas de la retina viables restantes podrían permitir la recuperación de la visión en pacientes que de otro modo serían ciegos. En otras palabras, la terapia con células madre está dirigida al tratamiento de las degeneraciones de la retina en aquellas situaciones en las que se han perdido los fotorreceptores y, por lo tanto, no es posible restaurar la funcionalidad a través de enfoques más comunes como la terapia de reemplazo de genes. Se han desarrollado y caracterizado células madre embrionarias humanas (hESC) o células madre pluripotentes inducidas (iPSC) derivadas de células precursoras de fotorreceptores (PRPC) contenidas en organoides de retina (RO) para terapias experimentales regenerativas. Aunque la terapia con células madre es un campo que ha mostrado resultados prometedores en animales de laboratorio, no hay informes que evalúen la seguridad y eficacia de su uso en perros. Con un inyector subretiniano que fue modificado para acomodar el gran tamaño de los agregados celulares, inyectamos con éxito las células en el espacio subretiniano (SRS) canino utilizando un procedimiento quirúrgico sencillo (inyección manual en bolo sin vitrectomía previa). Pudimos monitorizar la supervivencia y las características de las células injertadas a lo largo del tiempo utilizando un enfoque de imagen multimodal que incluía la detección mediante fotografía del fondo de ojo y/o cSLO de los genes reporteros fluorescentes (tdTomato o GFP) expresados por las PRPC. Esto nos permitió superar un reto importante encontrado en otros estudios, donde las células donantes no fluorescentes fueron seguidas sólo por OCT o detectadas por histología después de la terminación. La visualización de las PRPC fluorescentes en el animal vivo nos permitió diferenciarlas de las células del huésped. En consonancia con lo descrito anteriormente, observamos dos patrones temporales de pérdida de células del donante: una reducción temprana del número de células injertadas en la primera semana del trasplante que no dependía del estado de la inmunosupresión (IS), y un rechazo retardado del injerto, observado en aquellos perros que no estaban inmunosuprimidos. De hecho, hasta donde sabemos, no hay estudios que evalúen el tiempo de pérdida de fotorreceptores tras el trasplante, con y sin IS, controlando simultáneamente la transferencia de material citoplasmático entre las células del donante y del huésped. Aquí observamos signos compatibles con el rechazo del trasplante en animales que no recibieron IS sistémico, así como en un único perro cuyo tratamiento con IS se interrumpió. El grado de inflamación clínica variaba entre los animales, pero la vasculitis retiniana, el vítreo turbio y la inflamación de la retina eran comunes en todos los perros con rechazo de las células del donante. Estos signos se detectaron por primera vez entre 1-2 y 12 semanas después del trasplante, lo que respalda la necesidad de un seguimiento frecuente de las retinas tratadas en los meses siguientes al trasplante para detectar posibles signos tempranos de rechazo y ofrecer la oportunidad de ajustar el régimen inmunosupresor. Dado que el rechazo del trasplante en el SRS también puede producirse sin inflamación clínica manifiesta, se justifica la identificación de nuevos biomarcadores que puedan detectar la inflamación subclínica temprana para modular la respuesta inmunitaria y prolongar la supervivencia del injerto. Aunque se desconocen todos los factores que promueven la supervivencia de las células del donante, descubrimos que el IS sistémico desempeñaba un papel fundamental en la supervivencia de las hESC-PRPCs administradas por vía subretiniana, como se había informado anteriormente. En el presente estudio, algunas PRPC desarrollaron estructuras similares a pedículos, expresaron la proteína presináptica sinaptofisina y establecieron contactos con las células bipolares del anfitrión. Estos resultados alentadores preparan ahora el terreno para la evaluación funcional de estas xenosinapsis. La retinosis pigmentaria es un grupo de enfermedades genéticas que provocan una pérdida progresiva de la visión, siendo una de las principales causas de ceguera en los países desarrollados. Está bien documentado que en pacientes con retinosis pigmentaria, existe una disfunción vascular asociada que conduce al adelgazamiento de los vasos; sin embargo, las implicaciones de esta disfunción vascular en la degeneración de los fotorreceptores no se comprenden completamente. Los modelos caninos de degeneraciones retinianas hereditarias han sido de gran relevancia en el desarrollo traslacional de terapias de reemplazo génico para múltiples formas de retinosis pigmentaria, Amaurosis congénita de Leber, y enfermedad de Best. De manera similar a lo que ocurre en pacientes con retinosis pigmentaria, los perros afectados con las mismas mutaciones también experimentan remodelación vascular, sin embargo, la cinética de esta remodelación vascular en enfermedades retinianas hereditarias caninas no se ha estudiado y no se han establecido los parámetros normales en el perro. La angiografía por tomografía de coherencia óptica (OCTA) es un método novedoso de obtención de imágenes sin necesidad del uso de contraste intravenoso que permite la visualización detallada de la circulación retiniana, lo que permite el estudio de los distintos plexos vasculares por separado. Esta importante extracción de imágenes de los diferentes plexos, junto con la alta resolución de estos angiogramas, permite una cuantificación más precisa de la densidad vascular y otros parámetros, teniendo muchas aplicaciones en sujetos sanos y en pacientes con diferentes enfermedades oculares y sistémicas. Con el uso de modernas técnicas de imagen, este trabajo ha confirmado la presencia de cuatro plexos retinianos distintos. Aunque muchos estudios han informado de los datos cuantitativos de las imágenes OCTA en retinas humanas, no se han descrito parámetros vasculares caninos. Este estudio proporciona datos normativos para el SVP+ICP, DCP y WR, estableciendo con éxito un rango de referencia que puede ser consultado y comparado en futuros estudios. En los ojos humanos, el número de plexos retinianos y sus densidades disminuyen hacia la periferia, y esto es similar a lo que Engerman et al. describieron previamente en perros. Nuestro trabajo no sólo confirma este hallazgo, sino que ahora proporciona datos cuantitativos para cuatro parámetros que se utilizan frecuentemente para caracterizar las redes vasculares. En nuestra evaluación, los angiogramas de OCTA tenían una mayor resolución en comparación con las imágenes de AF en la misma localización. Al igual que en el caso de los seres humanos, la angiografía por OCT en perros permitió identificar lechos capilares (ICP y DCP) que no se identificaban con la AF. Sin embargo, la AF proporcionó un mayor campo de visión y los artefactos que se encontraron en algunas de las exploraciones de OCTA (artefactos de movimiento y anormalidades de descorrelación debido al artefacto de proyección) no se observaron en las imágenes de AF. Cuando se compara con las imágenes obtenidas por IHC en montajes completos de retina, nuestro estudio confirma que la OCTA proporciona una buena visualización de la SVP y la DCP. También encontramos que había una subrepresentación de los vasos de pequeño calibre en la OCTA, especialmente los situados en capas altamente reflectantes (ICP). Cuando se compara con las imágenes adquiridas en las mismas localizaciones por microscopía confocal/IHC, nuestros resultados sugieren que la OCTA es una técnica valiosa para visualizar y cuantificar la vasculatura retiniana en perros, especialmente para el análisis de la VD en el DCP. Además, por IHC encontramos que el ICP se fusiona con el SVP pero no con el DCP como ocurre en las retinas humanas. Nuestro estudio ha confirmado la viabilidad del uso de OCTA en perros, proporcionando imágenes resueltas en profundidad de diferentes capas retinianas segmentadas que permiten la evaluación de plexos individuales. Esto allana el camino para otros análisis in vivo de la vasculatura de la retina canina en un amplio número de patologías de la retina con un fenotipo vascular. Además, evaluamos los cambios vasculares en el area centralis de perros afectados por varias formas de IRD que fueron visualizados por OCTA en diferentes etapas de la enfermedad. Identificamos que la DCP está más afectada que las redes vasculares más superficiales en una etapa temprana de la enfermedad. Además, confirmamos que existe una fuerte asociación entre el VD en el DCP y el grosor de la ONL, lo que sugiere que la evaluación de la vascularización en este plexo puede utilizarse como un marcador indirecto para la evaluación de los requisitos metabólicos de la retina externa. Por último, hemos validado mediante el análisis de los vasos en los montajes planos de la retina los hallazgos de la OCTA, y hemos descubierto que en los modelos caninos de IRD la migración de las células del RPE también desempeña un papel en las alteraciones vasculares de la fase posterior que se producen en los pacientes con RP. Encontramos que los cambios microscópicos observados en los vasos con degeneración eran diferentes en las distintas redes retinianas. En la DCP, se confirmó un estrechamiento y una pérdida progresiva de vasos, que acabó con la desaparición completa de esta red. En el SVP de los tres modelos, los vasos presentaban un mayor grosor de la pared debido a la deposición de material que rodea la pared vascular que, en las fases finales, conduce al estrechamiento y la oclusión vascular. En la fase final de la enfermedad, se observó que múltiples vasos de la SVP estaban rodeados de estructuras pigmentadas. El marcaje específico de RPE65 reveló que se trataba de células del PRE que habían migrado para rodear estos vasos internos de la retina. Aquí caracterizamos dos tipos diferentes de degeneración vascular que se producen en los plexos retinianos SVP y DCP, lo que podría aportar información para futuros estudios que evalúen específicamente la fisiopatología de esta degeneración vascular. Un animal del modelo crd2/NPHP5 fue tratado con terapia de reemplazo génica unilateralmente con una inyección subretiniana que cubría el area centralis. En este perro, la pérdida de ONL en el momento de la intervención de terapia génica era inferior al 50%. Al comparar las fotografías del fondo de ojo del ojo no tratado y el tratado, se identificó fácilmente una marcada preservación de la vascularización en el área que fue cubierta por la terapia génica. Las imágenes OCTA se procesaron con el programa AngioTool, y la evaluación cualitativa de las imágenes esqueletizadas mostró una regresión vascular en el ojo no tratado y una notable preservación de la integridad vascular en el ojo tratado. También demostramos que en estas enfermedades naturales, así como en un modelo de degeneración aguda de fotorreceptores inducido por la luz, el DCP se ve afectado antes que los otros plexos vasculares de la retina. La posterior disminución de la VD en el SVP+ICP que se produce en las últimas fases de la degeneración, es probablemente una respuesta al marcado adelgazamiento de la retina externa y a la capacidad de que el oxígeno transportado por los vasos coroideos llegue a las localizaciones internas de la retina, como se ha confirmado previamente en modelos animales felinos utilizando perfiles espaciales de oxigenación de la retina.

Åldersrelaterad makuladegeneration (AMD) är en kronisk ögonsjukdom och är den vanligaste orsaken till irreversibel synnedsättning hos äldre personer i den industriella världen. Bakomliggande orsaker kan vara både genetiska och miljömässiga varför prevention och behandling av ögonsjukdomar kan öka livskvaliteten samt minska nedsatt syn och de funktionshinder som synnedsättning medför. Syftet med studien var att belysa ögonsjuksköterskans hälsofrämjande arbete med patienter som har åldersrelaterad makuladegeneration. Denna integrativa litteraturstudie visade att kunskapsnivån om AMD var låg både hos den allmänna befolkningen och patienter. Även patienter med allvarlig synnedsättning på grund av en eller flera ögonsjukdomar var omedvetna om sin diagnos. Patienter med AMD upplevde att de inte fick tillräckligt med information om sjukdomen, riskfaktorer, undersökningar och vilka behandlingar som fanns. Att drabbas av AMD innebar en stor påverkan på patienternas livskvalitet. Det visade sig att det fanns ett starkt samband mellan förlust av synfunktionen och symtom på depression. Ingen av studierna var från Sverige eller belyste svenska förhållanden men belyser vikten av att hälsofrämjande arbete och ökad medvetenhet kring kroniska ögonsjukdomar och dess riskfaktorer är mycket viktigt. Det vore av stort intresse att undersöka de svenska förhållandena som jämförelse. / Age-related macular degeneration (AMD) is a chronic eye disease and is the most common cause of irreversible vision loss amongst elderly people within the industrial world. Underlying causes can be both genetical and environmental, prevention and treatment of AMD can increase quality of life and reduce visual impairment and all dysfunctionalities related to it. The aim of this study was to highlight ophthalmic nurses' health promoting work with patients with age-related macular degeneration. This integrative literature review showed that the level of awareness of AMD was low among both the general population and patients. Even patients with severe vision loss due to one or several eye diseases was unaware of their diagnosis. Patients with AMD felt that they were not given enough information about the disease, the risk factors, available health examinations and what possible treatments were available. To be affected with AMD entails a significant negative effect on patients quality of life. It was shown that there was a strong connection between vision loss and symptoms of depression. None of the studies were from Sweden or highlighted the Swedish conditions but highlights the importance of health promotion, awareness about chronic eye disease and its risk factors as very important. It would be of great interest to investigate the Swedish conditions for comparison.

Thesis (PhD (Biomedical Sciences. Medical Physiology))--Stellenbosch University, 2008. / The overall objective of this thesis is to provide additional data to assist clinicians and experimental neurologists alike in the quest for better understanding, more accurately diagnosing and more successfully treating patients suffering from Parkinson’s disease (PD). The general theme of the thesis is the interaction between certain environmental stimuli, including the exposure to adverse events during early central nervous system (CNS) development and the manifestation of elements of neurodegeneration, whether by means of neurochemical changes or expressed as a dysfunctional voluntary motor system. The first chapter provides a general introduction to the research theme of the thesis. This includes, in particular, a discussion on current understanding concerning the etiology and clinical profile of PD, the relative contribution made by genetic factors compared to environmental ones, and current treatment strategies for treating the disease. Mention is also made of the failure of these therapeutic applications for reversing or protecting against the disease, due to the side-effects associated with them. The material covered in chapter 1 provides the basis for the more complete discussion concerning these various aspects, contained in the chapters to follow. The overall aim was also to characterise the effects of commonly used toxin-induced animal models of PD, and the extent of vulnerability that the CNS displays towards them. The destruction of dopaminergic neurons following the administration of 6-OHDA at targeted points along the nigrostriatal tract is used extensively to model PD pathology in rats and is an established animal model of the disease. However, mature or even aged animals are mainly used in these studies, while the effects that the toxin might have on the developing CNS remain unclear. The study reported in chapter 4 aimed to elucidate some of 6-OHDA’s actions on the young adolescent (35 days-old) CNS by comparing the motor and biochemical effects of a unilateral infusion of the toxin into two anatomically distinct basal ganglia loci: The medial forebrain bundle (MFB) and the striatum. Animals were randomly assigned to receive either a direct delivery of 6-OHDA (12μg/4μl) into the MFB or an indirect injection, into the striatum. Although both lesion types were used, the MFB model is considered a more accurate portrayal of end-stage PD, while the striatum-model better reflects the long-term progressive pathology of the disease. The different lesions’ effects on motor function were determined by observing animal’s asymmetrical forelimb use to correct for weigh shifting during the vertical exploration of a cylindrical enclosure. Following the final behavioral assessment, the concentration of dopamine (DA) and DA metabolites remaining in the post-mortem brains were determined using 4 HPLC electrochemistry (HPLC-EC) and the levels compared between the two groups. The HPLC-EC results revealed a compensatory effect for DA production and DA turnover on the lesioned hemisphere side of the toxin-infused animal group. Thus, following 6-OHDA treatment, there appears to be extensive adaptive mechanisms in place within the remaining dopaminergic terminals that may be sufficient for maintaining relatively high extracellular and synaptic concentrations of DA. However, since substantial changes in motor-function were observed, it is suggested that the capacity of the remaining dopaminergic neurons to respond to increased functional demands may be limited. In addition, the behavioral results indicate that the distinct indices relating to different functional deficits depend on the lesioning of anatomically distinct structures along the nigrostrial tract. It has long been known that far fewer women are diagnosed with PD than men are. This seeming protection offered to females against degenerative disease of the CNS may relate to estrogen, although the hormone’s mechanism of action on the dopaminergic system is poorly defined. With an estimated 10-15 million women using oral contraceptives (OCs) in the United States alone, the aim of chapter 2 was to examine the evidence for a possible relationship between PD and the female reproductive hormone estrogen. A review of the current literature available on the topic was performed by consulting Medline, and by performing a search of the case-reports contained within the World Health Organization’s (WHO) International Drug Monitoring database, for possible PD-related symptoms that may arise from estrogen replacement therapy (ERT). The results, whilst conflicting, seem to suggest that estrogen protects women from obtaining the disease, or at least some features of it. Intensive research efforts are called for, with sufficient power to establish the relationship between ERT and the onset and development of parkinsonism. Chapter 3 reports on the results obtained from an experiment that subjected young Sprague-Dawley rats, 35 days of age, to a lower and a higher dose of 6-OHDA delivered to the MFB. Control rats received equivalent saline infusions. At 14 days post-surgery, the rats were evaluated for forelimb akinesia. For the higher dose of 6- OHDA the female rats were less impaired than males in making adjustment steps in response to a weight shift and in the vibrissae-evoked forelimb placing test. In addition, Tyrosine hydroxylase (TH) immunoreactivity was significantly higher for the female rats. Early gender differences in cell survival factors and/or other promoters of neuroplasticity may have contributed to the beneficial outcome seen in the females. For example, nerve growth factor (NGF) was found to be higher in the female rats following administration of the DA neurotoxin. It is unclear whether gonadal steroids are involved, and, if so, whether female hormones are protective or whether male hormones are prodegenerative. Determining the mechanisms for the improved outcome seen in the young female rats may lead to potential treatment strategies against PD. 5 Many studies have shown that early life stress may lead to impaired brain development, and may be a risk factor for developing psychiatric diseases, including clinical depression. However, few studies have investigated the impact that early stress may have on the onset and development of neurodegenerative disorders such as PD. The study reported on in chapter 5 conjointly subjected rat pups to a maternal separation (MS) paradigm that is a well characterised model of adverse early life events, and a unilateral, intrastriatal injection of 6- OHDA. The combined effects of these models on motor deficits and brain protein levels were investigated. Specifically, the animals were assessed for behavioral changes at 28 days postlesion with a battery of tests that are sensitive to the degree of DA loss sustained. The results show that animals that had been subjected to MS display poorer performance in the vibrissae and single-limb akinesia test compared to non-MS control animals (that had also been subjected to the toxin exposure). In addition, there was a significant increase in the loss of TH staining in MS rats compared to non-MS ones. The results from this study therefore suggest that exposure to adverse experiences during the early stages of life may contribute towards making dopaminergic neurons more susceptible to subsequent insults to the CNS occurring during mature stages of life. Therefore, taken together, early exposure to stress may predispose an individual towards the onset and development of neurodegenerative disease, which especially becomes a threat during the later stages of adult life. Moreover, within the framework of these characteristics, the capacity of a widely-used pharmacological agent (statins) was tested for possible future therapeutic application in PD (chapter 7). Although the precise cause of sporadic PD remains an enigma, evidence suggests that it may associate with defective activity of complex I of the mitochondrial electron transport chain. Mitochondrial DNA transmit and express this defect in host cells, resulting in increased oxygen free radical production, depressed antioxidant enzyme activities, and greater susceptibility to apoptotic cell death. Simvastatin is a member of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) group of drugs that are widely used for lowering cholesterol levels in patients who display elevated concentrations of low-density lipoprotein cholesterol. The study aimed to investigate the effects that statin-treatment have on motor-function and at the mitochondrial-protein level, using rotenone, a mitochondrial complex I inhibitor, as a rat-model of PD. Adult male Sprague-Dawley rats were treated either with simvastatin (6mg/day for 14 days) or with a placebo. Two different tests to assess motor function were used: The apomorphine-rotation test, and the vibrissae-elicited forelimb placement test. Following the drug administration protocol, the nigrostriatal tract was unilaterally lesioned with either rotenone (3 μg/4 μl) or, for the controls, were sham-operated by infusing the vehicle (DMSO:PEG) only. Five days later the rats were killed and a highly purified concentration of isolated mitochondria was prepared from the substantia nigra (SN) sections. 2- 6 Dimensional electrophoresis (2-DE) with subsequent identification of the spots using electronspray ionization quadruple time-of-flight mass spectrometrical (ESI-Q-TOF MS) was performed and the results BLAST-searched using bio-informatics tools for naming the identified peptides. The motor test results indicate that while unilateral rotenone causes behavioral asymmetries, treatment with simvastatin improved motor function relative to the rotenoneinduced ones. Mass Spectroscopy identified 23 mitochondrial proteins that differ significantly in protein expression (p < 0.05) following simvastatin treatment. The altered proteins were broadly classified according to their cellular function into 6 categories, with the majority involved in energy metabolism. This study effectively illustrated how neuroproteomics, with its sophisticated techniques and non-biased ability to quantify proteins, provides a methodology with which to study the changes in neurons associated with neurodegeneration. As an emerging tool for establishing disease-associated protein profiles, it also generates a greater understanding as to how these proteins interact and undergo post-translational modifications. Furthermore, due to the advances made in bioInformatics, insight is created concerning their functional characteristics. Chapter 4 summarises the most prominent proteomics techniques and discuss major advances made in the fast-growing field of neuroproteomics in PD. Ultimately, it is hoped that the application of this technology will lead towards a presymptomatic diagnosis of PD, and the identification of risk factors and new therapeutic targets at which pharmacological intervention can be aimed. The final chapter (chapter 8) provides a retrospective look at the academic work that had been performed for the purpose of this thesis, recaps on the main findings, and also highlights certain aspects of the project and provides relevant suggestions for future research. Lastly, the appendix provides a detailed overview of the methods followed for the experiments described in this thesis. It provides not only a comprehensive description of the techniques that had been followed, but provides information concerning the care taken with the animals (i.e. post-surgery) in order to control for the potential influence of experimental variables on the results.

The plasma protein complement factor H (fH, 155 kDa) regulates the activity of the alternative pathway of complement activation. Factor H is monomeric, and its 20 CCP modules are arranged in a predominantly elongated conformation, joined by linking sequences that vary in length, with the longest linkers occurring in the central portion of the molecule. CCP modules 1 through 4 of fH host its capacity to act as a cofactor for fI-mediated proteolytic degradation of C3b and its ability to accelerate the decay of the C3 convertase, C3bBb, thereby regulating the so-called tick-over activation of the alternative pathway. Mutations in this part of fH might compromise its function and lead to underregulation of the alternative pathway. It is hypothesized that this can cause predisposition to diseases such as atypical haemolytic uraemic syndrome (aHUS) and age-related macular degeneration (AMD). In the current work, the known disease-associated mutations R53H and R78G were compared to wild-type in terms of fluid-phase cofactor assays, C3b-binding affinity and the ability to accelerate the decay of the convertase. In addition, the protective variant, I62, was also inspected because its protective role might be explained by an increased regulatory activity. The second, linked, aim of this project was to employ Forster resonance energy transfer (FRET) to study the link between conformation and function in fH. FRET is valuable for obtaining long-distance restraints up to a maximum of 100 °A and is therefore particularly useful for inferring domain orientations within multidomain proteins. This approach to measure long-range inter- and intramolecular distances is a convenient way to complement NMR-based structural investigations, which rely on short-range restraints. It is also a valuable complement to X-ray crystallography since it is a solution technique that can be conducted under physiological conditions. By using site-directed mutagenesis in the current work, free cysteines were introduced into CCP modules 1-4 at strategic points, which were then used for attachment of fluorescent tags. C3 possesses an internal thioester which can be labelled with a fluorophore upon activation to C3b. Intermolecular FRET measurements were thus undertaken to gain information about the interaction between the two proteins that is crucial for understanding functional activity. The CCP modules in the centre of fH may be responsible for introducing a bend into fH that brings the N-teminus close to the C-terminus (the latter is important for host versus non-host discrimination) joined by the longest linkers occurring in the whole molecule. This coincidence of two relatively small CCP modules, 12 and 13, with the highest number of eight amino acids between them, is hypothesised to reflect some unique architectural features. To explore the structural details of this portion of fH by FRET, single-labelled cysteine mutants were further modifed to provide a recognition site for transglutaminase (TGase), which can be enzymatically labeled with a second fluorophore. This stoichiometrically-labelled protein was used for intramolecular FRET studies.

The aims of this study were to analyse known and potential biomarkers of common and genetically complex human disorders and to identify genetic and environmental variation associated with plasma biomarker concentrations. Two groups of protein biomarkers were analysed. First, plasma complement factor H (CFH) was selected as a potential biomarker for age-related macular degeneration (AMD), since common variants in the CFH gene show strong association with this disorder. Secondly, two isoforms of amyloid-β (Aβ40 and Aβ42) were selected as biomarkers for Alzheimer disease (AD) since Aβ deposits are major constituents of the amyloid plaques characteristic of this disorder. Physiological and anthropometric measurements and samples of human and genomic DNA were collected from a population sample of 1,021 individuals from the Croatian island of Vis. Quantitative determination of plasma Aβ40 and Aβ42 concentrations was performed using enzyme-linked immunosorbent assays. Heritabilities and significant covariate effects were estimated for each trait in the Croatian data set. Genome-wide linkage and association analyses were conducted for the biomarker traits. A novel finding was the genome-wide significant association between a CFH and several polymorphisms close to and within the CFH gene. The strongest association was with an intronic SNP within CFH, which explained 28% of the total trait variance (P < 10-50). The association was also replicated in a Dutch sample set. A SNP haplotype was identified which accounted for a higher proportion of the phenotypic variance. Conditional haplotype analysis showed that the effect of this haplotype on plasma CFH concentration was independent of the CFH Y402H variant, and significantly stronger than a deletion of the adjacent CFHR3/CFHR1 which was already known to affect AMD susceptibility. Genetic analysis of 382 AMD cases and 201 controls was consistent with the CFH Y402H variant being the strongest AMD susceptibility locus. Variation in plasma CFH concentration was found to explain up to 1.8% of the variation in susceptibility to AMD with an odds 2.1 (95% C.I. 1.3-3.4, P = 0.003). SNPs that were strongly associated with a CFH concentration also influenced AMD susceptibility (P < 0.05) independently of the CFH Y402H polymorphism. Functional analysis of genomic regions associated with plasma CFH is needed to identify the causal variants. Associations were observed between plasma Aβ40 concentration and several novel candidate loci, spanning regions of approximately 0.2 Mb, on chromosomes 9 and X. Similarly, novel associations with plasma Aβ42 were found in several regions, each spanning 0.2-0.4 Mb, on chromosomes 2, 5, 9, 15 and 20. The proportion of the phenotypic variance in plasma Aβ42 explained by these putative associations ranged between 1.8 and 2.8%. However, none of the associated SNPs was significant after correction for multiple testing, therefore replication is required. Finally, attempts were made to identify and quantitate new protein biomarkers of disease in human plasma using mass spectrometry. Development and optimisation of techniques was initially undertaken to deplete high-abundance plasma proteins and improve signal:noise ratio. This allowed the assessment of downstream proteomic approaches including MALDI-TOF mass spectrometry (MS), capillary electrophoresis (CE) and ion exchange chromatography (IEC), each with the potential for large-scale quantitation of plasma proteins. Although the analysis of single protein analytes, using CE and IEC proved promising, the results highlighted the difficulty associated with MALDI-TOF and protein ionisation techniques in analysing complex mixtures such as plasma.

In patients with age-related macular degeneration, a monolayer of cells in the eyes called retinal pigment epithelium differ from healthy ones in morphology. It is therefore important to quantify the morphological changes, which will help us better understand the physiology, disease progression and classification. Classification of the RPE morphometry has been accomplished with whole tissue data. In this work, we focused on the spatial aspect of RPE morphometric analysis. We used the second-order spatial analysis to reveal the distinct patterns of cell clustering between normal and diseased eyes for both simulated and experimental human RPE data. We classified the mouse genotype and age by the k-Nearest Neighbors algorithm. Radially aligned regions showed different classification power for several cell shape variables. Our proposed methods provide a useful addition to classification and prognosis of eye disease noninvasively.